Humacyte, Inc. (HUMA)
NASDAQ: HUMA · Real-Time Price · USD
1.090
-0.060 (-5.22%)
At close: Mar 5, 2026, 4:00 PM EST
1.090
0.00 (0.00%)
Pre-market: Mar 6, 2026, 7:40 AM EST
Humacyte Revenue
Humacyte had revenue of $753.00K in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $1.57M.
Revenue (ttm)
$1.57M
Revenue Growth
n/a
P/S Ratio
133.91
Revenue / Employee
$7,141
Employees
220
Market Cap
210.37M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Arcturus Therapeutics Holdings | 97.60M |
| Voyager Therapeutics | 31.32M |
| MediWound | 20.93M |
| Crescent Biopharma | 10.84M |
| Prelude Therapeutics | 10.50M |
| Ovid Therapeutics | 6.61M |
| Camp4 Therapeutics | 3.80M |
HUMA News
- 4 days ago - Humacyte To Participate in Upcoming Investor Conferences - GlobeNewsWire
- 16 days ago - Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting - GlobeNewsWire
- 25 days ago - Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels - GlobeNewsWire
- 2 months ago - Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications - GlobeNewsWire
- 2 months ago - Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel - GlobeNewsWire
- 2 months ago - Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair - GlobeNewsWire
- 2 months ago - Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital - GlobeNewsWire
- 3 months ago - Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results - GlobeNewsWire